Posted inHealth Care

FDA’s controversial approval of Alzheimer’s drug draws calls for reform

WHEN MASS GENERAL BRIGHAM announced two weeks ago that it would not offer a controversial new drug treatment for Alzheimer’s disease to patients, it was an important statement from the state’s leading provider network. On Thursday, Blue Cross Blue Shield of Massachusetts, the state’s largest private insurer, said it won’t cover the drug developed by […]